Glomerulonephritis
Initiate earlier treatment
Pulmonary renal syndrome (PRS) is characterized by rapidly progressive glomerulonephritis (RPGN) and diffuse alveolar hemorrhage secondary to an autoimmune response. The most common causes of PRS in adults are ANCA-associated vasculitis (AAV) and anti-GBM disease. Due to the overlap in clinical presentation, frequency of RPGN, and the need for early diagnosis and treatment, testing for ANCA and anti-GBM is recommended during the differential diagnosis.
Glomerulonephritis test menu
Glomerulonephritis
Prompt identification of ANCA and anti-GBM antibodies allows for early initiation of treatment and may improve patient outcomes. Antibodies to GBM antigens cause glomerulonephritis, Goodpasture’s syndrome, and, less commonly, pulmonary hemosiderosis. Anti-neutrophil cytoplasmic antibodies occur in various types of autoimmune diseases including renal limited vasculitis (e.g., Wegener’s granulomatosis [WG] or microscopic polyangiitis [MPA]) and pauci-immune necrotizing GN.1 Comprehensive testing, prompt result reporting, and access to more than 150 years of advanced medical knowledge deliver the answers your practice needs to keep care local.
Key testing
- GBM | Glomerular Basement Membrane Antibodies, IgG, Serum
- Identifies GBM antibodies to aid in diagnosing anti-GBM disease or Goodpasture’s syndrome.
- Evaluates patients with rapid-onset renal failure and evidence of possible anti-GBM disease.
- Evaluates patients with suspected nephritic syndrome and active urinary sediments to determine the clinical presentation.
- Evaluates patients with pulmonary hemorrhage.
- Guides treatment plan development.
- Monitors treatment effectiveness and progression of renal injury in patients with anti-GBM diseases.
- Confirms diagnosis in conjunction with the Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum (Mayo ID: VASC).
- VASC | Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum
- Distinguishes Wegener’s granulomatosis from microscopic polyangiitis by identifying the presence of antineutrophil cytoplasmic antibodies.
- Confirms disease subtype when a patient presents with nephritic syndrome.
- Establishes if a patient with anti-GBM disease is also ANCA positive to predict outcomes.
- Guides treatment plan development.
- Confirms initial diagnosis in conjunction with Glomerular Basement Membrane Antibodies, IgG, Serum (Mayo ID: GBM).